Adolescent HIV prevalence, sexual risk, and willingness to participate in HIV vaccine trials
Adolescent HIV prevalence, sexual risk, and willingness to participate in HIV vaccine trials
复制标题
DOI：
10.1016/j.jadohealth.2006.05.016
复制
发表时间：
2006-11-01
影响因子：
7.6
通讯作者：
Bekker, Linda-Gail
中科院分区：
文献类型：
--
作者：
Jaspan, Heather B.;Berwick, Jessica R.;Bekker, Linda-Gail
目的：确定南非开普敦附近一个城郊社区11 - 19岁青少年的人类免疫缺陷病毒（HIV）患病率、性风险行为和对HIV疫苗试验的态度。方法：我们对口服漏出液进行HIV抗体检测，并使用自填问卷评估性风险行为和参与HIV疫苗试验的意愿。结果：在选定的510名青少年中，有356人（73%）参加了研究。该组的HIV感染率为10.6%（95%置信区间[CI] 7.5 - 14.4）。三分之一的青少年经历过初次性行为，平均年龄为14.6岁。终生性伴侣数量与HIV感染独立相关（比值比[OR]= 1.62; 95%CI 1.1 - 2.3）。在多变量分析中，年龄增加、女性性别和上学与发生性行为独立相关。大多数青少年（79%）愿意参加艾滋病毒疫苗试验。年龄的增长和在社区居住时间的增加与参与意愿显著相关（OR = 1.19，95%CI1.01-1.4和OR = 1.14，95%CI1.03-1.26）。需要针对青春期前的艾滋病毒疫苗。在这种情况下，青少年的艾滋病毒疫苗试验将因他们愿意参与而得到促进。(c)2006年，为青少年医学会。All rights reserved.
Purpose: To determine human immunodeficiency virus (HIV) prevalence, sexual risk behaviors, and attitudes toward HIV vaccine trials among 11-19 year-olds in a peri-urban community near Cape Town, South Africa.Methods: We per-formed HIV antibody testing on oral transudate, and assessed sexual risk behaviors and willingness to participate in HIV vaccine trials using self-administered questionnaires.Results: Of the 510 adolescents selected, 356 (73%) participated. The HIV prevalence of the group was 10.6% (95% confidence interval [CI] 7.5-14.4). One-third of adolescents had experienced sexual debut, with a mean age of 14.6 years. Number of lifetime sexual partners was independently associated with HIV infection (odds ratio [OR) = 1.62; 95% CI 1.1-2.3). In a multivariate analysis, increasing age, female gender, and attending school were independently associated with having had sex. The majority of adolescents (79%) were willing to participate in an HIV vaccine trial. Increasing age and length of residence in the community were significantly associated with willingness to participate (OR = 1.19; 95% CI 1.01-1.4 and OR = 1.14; 95% CI 1.03-1.26, respectively).Conclusions: The prevalence of HIV and risk behavior among adolescents in this community is high. HIV vaccines are required that target preadolescents. HIV vaccine trials in adolescents in this setting will be facilitated by their willingness to participate. (c) 2006 Society for Adolescent Medicine. All rights reserved.